24.05.2013 - GSK has entered into a public-private partnership with the federal US agency BARDA to develop new antibiotics and drugs against potential bioweapons.
The first-ever public-private partnership of the Biomedical Advanced Research and Development Authority (BARDA) with a pharma company could be worth up to US$200m if the collaboration proves effective after 18 months. The two partners will jointly develop anti-infectives to treat infections with bugs that have become a medical threat due to their resistance to common antibiotics. Additionally, the collaboration aims at developing drugs against pathogens that could become a civil threat due to their potential use as a bioweapon. Both topics are priorities of the National Health Security Strategy as well as the BARDA’s 2011-2016 working plan.
The initial funding for the Public-Private Partnership of US$40m for the first 18 months will give GSK the possibility to further develop promising candidates from its antibiotics portfolio with a lowered investment risk for the drugmaker. While return-on-investment in the antibiotics space has become low, most large drug-makers have focused on more lucrative and financially less risky disease areas. David Payne, head of GSK's antibacterial discovery unit, said public-private partnerships, like the one with BARDA, were a key part to solving the problem.
GSK is already involved in the Innovative Medicine’s Initiative’s programme against antibiotic resistance. But while the IMI programme is focused on bringing Phase III drugs to the market and to find strategies against Gram-negative bacteria, the compounds covered by the BARDA deal are still in early safety testing.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more